In a groundbreaking development poised to revolutionize the field of proteomics, researchers have unveiled a novel method that achieves single-molecule peptide sequencing with unparalleled resolution. This innovative approach transcends current limitations in protein analysis by converting the complex challenge of peptide sequencing into a DNA sequencing problem, leveraging the mature and highly sensitive technologies available for nucleic acid analysis. The technique, presented by Zheng et al. in Nature Biotechnology, offers a pathway toward high-throughput, de novo sequencing of proteins, a feat that has eluded scientists despite decades of advances in mass spectrometry and emerging single-molecule methods.
The central obstacle in proteomics has long been the accurate, high-throughput sequencing of proteins at the single-molecule level. Unlike DNA or RNA sequencing, proteins lack a natural amplification process, and their diverse chemical structures complicate direct reading at molecular precision. Existing methods like mass spectrometry—invaluable yet limited in sensitivity and throughput—struggle to reliably resolve sequences and post-translational modifications at the single molecule scale. The new approach tackles these challenges head-on by ingeniously reverse-translating peptides into DNA, effectively harnessing the power and precision of next-generation sequencing technology.
At the heart of this technology lies a modified Edman degradation process, a classical peptide sequencing chemistry adapted for contemporary biotechnology. In this process, peptides undergo iterative cycles wherein the N-terminal amino acid is chemically cleaved, but with a twist: each liberated amino acid is covalently tagged with a unique DNA barcode corresponding to that specific peptide sequence. This DNA tagging strategy establishes a direct physical record of the amino acid’s identity and position, facilitating its subsequent detection and analysis through nucleic acid technologies rather than proteomic tools.
Following each Edman cycle, the DNA-barcoded amino acids are identified via antibody-mediated proximity extension assays (PEA). This advanced immunoassay technique exploits the high specificity of antibodies to recognize DNA tags and, through proximity ligation events, generates amplifiable DNA reporters. These reporters encode not only the amino acid’s identity but also its position along the peptide and the originating peptide molecule itself. The result is a DNA “readout library” that captures the linear sequence information initially present in the peptide.
Once converted into a DNA format, the sequence information is decoded using high-throughput sequencing platforms, turning the intimate chemical complexity of peptides into digital data streams. The approach benefits from the sensitivity, speed, scalability, and cost-efficiency inherent to modern nucleic acid sequencing technologies, effectively circumventing challenges posed by direct peptide sequencing. Millions of individual peptide reads are captured in parallel, enabling comprehensive coverage with a single experiment.
The robustness of this method extends beyond mere sequence identification. Researchers demonstrated accurate discrimination of native peptides as well as those bearing intricate post-translational modifications, including phosphorylation and glycosylation variants. This capability marks a significant leap forward since these modifications critically influence protein function and have historically been difficult to resolve at single-molecule resolution using conventional approaches.
Notably, this technology achieves true single-molecule sequencing—capturing peptide information at the finest granularity without ensemble averaging. Whereas traditional proteomic analyses aggregate signals from bulk peptide populations, obscuring individual molecular heterogeneity, the reverse translation method preserves molecule-specific data. This precision opens avenues for characterizing protein isoforms, identifying rare variants, and elucidating dynamic biochemical processes with unprecedented clarity.
The implications for biomedical research and clinical diagnostics are profound. Protein sequencing at the single-molecule level could dramatically enhance biomarker discovery, improve personalized medicine strategies by identifying unique proteoforms, and accelerate drug target validation. Furthermore, the approach provides a direct measure of protein sequences that circumvents reliance on genomic or transcriptomic inference, thus accurately reflecting functional proteomes shaped by complex post-translational landscapes.
From a technical perspective, the integration of Edman degradation chemistry with DNA barcoding and antibody-based proximity extension assays exemplifies sophisticated molecular engineering. This multidisciplinary convergence harnesses the specificity of proteolytic chemistry, the programmability of nucleic acids, and the sensitivity of immunoassays to build a seamless readout pipeline. The method elegantly leverages well-established biochemical reactions to convert an intractable problem into a manageable one through molecular innovation.
While challenges remain in scaling and automating these processes for widespread application, the conceptual breakthrough lays the foundation for next-generation proteomics instrumentation. Future developments may optimize the chemical tagging efficiency, enhance barcode library complexity, and refine antibody assays to improve throughput, accuracy, and sensitivity. Integration with existing sequencing infrastructures could facilitate rapid adoption in both research and clinical laboratories.
Moreover, the principle of reverse translation could extend beyond peptides to larger protein assemblies and complex proteomes, potentially enabling comprehensive proteomic profiling comparable to genomic studies. Such transformative capability would provide a molecular lens into biology, unraveling the detailed proteome dynamics that underpin health and disease states.
The innovation described by Zheng and colleagues represents a pivotal milestone that redefines protein sequencing paradigms. By translating peptide sequences into digital DNA outputs, the technology unlocks the vast potential of nucleic acid analytic tools for proteomic applications. The seamless interplay of chemical, immunological, and sequencing methods sets a new standard for sensitivity, resolution, and throughput in protein analysis.
As this technology matures, the scientific community anticipates paradigm-shifting advances in understanding proteomic complexity with single-molecule precision. The promise of truly comprehensive, high-resolution protein sequencing is now tangible, heralding a new era where protein science can march in lockstep with genomics and transcriptomics to reveal the full molecular choreography of life.
In conclusion, single-molecule peptide sequencing through reverse translation into DNA barcodes marks a seminal advance with sweeping implications. By surmounting longstanding technical obstacles, this method enables detailed characterization of peptide sequences and modifications at unprecedented scale and precision. Its deployment promises to invigorate research across biotechnology, medicine, and fundamental biology, establishing a transformative framework for decoding the proteome as a DNA sequencing problem.
Subject of Research: Single-molecule peptide sequencing and proteomics technologies
Article Title: Single-molecule peptide sequencing through reverse translation of peptides into DNA
Article References:
Zheng, L., Sun, Y., Hein, L.A. et al. Single-molecule peptide sequencing through reverse translation of peptides into DNA. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03061-z
Image Credits: AI Generated
